Introduction
============

Endoscopic resection (ER) is a curative therapy for superficial esophageal cancer (SEC) confined to the mucosa without lymphovascular (LV) invasion. On the other hand, additional therapies including esophagectomy, radiotherapy, and/or chemotherapy are used for non-curatively resected SEC, such as those with submucosal (SM) or LV invasion due to the substantial risk of nodal metastasis \[[@b1-ce-2018-025]-[@b3-ce-2018-025]\]. However, the necessity for additional therapy should be considered cautiously because of treatment-related complications and the occurrence of metachronous cancers. Surgical esophagectomy is associated with significant treatment-related mortality of 2.7%--13.3% \[[@b4-ce-2018-025]-[@b7-ce-2018-025]\]. In addition, subsequent cancer is an important cause of death among patients who undergo curative treatment for EC \[[@b8-ce-2018-025],[@b9-ce-2018-025]\].

In this case series, we report the long-term survival of and tumor recurrence in completely but non-curatively resected SEC patients. The outcomes of patients who were closely observed after non-curative ER were compared to those of patients who received additional therapies.

Materials and methods
=====================

Patients
--------

From a consecutively collected database of 209 patients with SEC who underwent ER from June 1999 to June 2014 at our hospital, we identified 24 cases of completely but non-curatively resected SEC with SM or LV invasion. The indications for some ER in these SEC patients included: (1) mucosa-confined tumors \<2 cm in size; and (2) intraepithelial tumors or high-grade dysplasia of any size. The patients were fully informed about the benefits and risks of ER and surgical esophagectomy. Surgical esophagectomy includes curative nodal dissection and is the standard treatment for SEC. However, ER has some advantages over surgery since it saves organ function and is minimally invasive. Written informed consent was obtained from all patients who underwent ER. In cases of non-curatively resected SEC after ER, surgical esophagectomy was recommended for the harvesting of regional nodes. If patients refused to undergo surgical esophagectomy, we provided additional treatment with radiotherapy and/or chemotherapy. Close observation alone was only permitted when the patient was medically unfit to receive additional therapy or refused any of the treatment options with an understanding of the risk of SEC recurrence. In the 24 patients with non-curatively resected SEC in the current study, 14 underwent additional treatments and 10 were placed on close observation. [Fig. 1](#f1-ce-2018-025){ref-type="fig"} presents a clinical flow chart for these patients. The study was approved by the institutional review board of Asan Medical Center (2016-1359).

Endoscopic procedure
--------------------

All tumors were evaluated by lugol chromoendoscopy or narrow-band imaging before ER, and SM invasion was assessed by endoscopic ultrasonography. The ER was performed using a single-channel endoscope (GIF-H260; Olympus Optical, Tokyo, Japan). After circumferential marking of the lesion, normal saline containing a mixture of epinephrine (0.01 mg/mL) and indigo carmine was injected into the SM layer and the lifted mucosa was circumferentially incised. Endoscopic SM dissection was performed using an insulated-tip knife 2 (IT knife; Olympus Optical) or IT knife (MTW Endoskopie, Wesel, Germany). Endoscopic mucosal resection was performed using a snare (SD-12U-1 or SD-9U-1; Olympus Optical) after circumferential incision. A UES-30 (Olympus Optical) or VIO 300D (Erbe Elektromedizin, Tübingen, Germany) system was used as the electrosurgical unit. Coagulation of all visible or bleeding vessels on the artificial ulcer was thoroughly performed using hemostatic forceps (FD-410LR; Olympus Optical).

Pathological definitions
------------------------

R0 *en bloc* resection was defined as the complete removal of the entire tumor without positive resection margins macroscopically and microscopically. Based on the R0 resection, curative resection for SEC was defined as the resection of tumors confined to the mucosa and the complete absence of SM or LV invasion on microscopic examination. Non-curative resection was defined as at least one instance of SM or LV invasion by the SEC on resection pathology \[[@b10-ce-2018-025]-[@b12-ce-2018-025]\].

Additional treatments and follow-up
-----------------------------------

Patients who showed non-curative resection on their final ER pathology were recommended to undergo additional treatments such as surgical esophagectomy, radiotherapy, and/or chemotherapy. Radiotherapy consisted of 45 Gy/25 fractions, and chemotherapy was based on cisplatin and capecitabine. Follow-up endoscopy was performed 3 and 6 months after ER and every 6 months thereafter. All patients underwent chest--abdominal computed tomography with contrast enhancement every 6 months to evaluate regional nodes or distant metastases. Metachronous EC was defined as tumors that developed at the esophagus other than the primary resection site at 1 year after ER.

Statistical analysis
--------------------

Variables are presented as a number (percentage) or as a mean±standard deviation. Student's t-test was used to compare continuous variables, and the chi-square or Fisher's exact test was used to examine categorical variables. Patient survival was calculated with the Kaplan--Meier method and compared with the log-rank test. All *p*-values were two-sided, and those \<0.05 were considered significant. All statistical analyses were performed using SPSS version 21 (SPSS Inc., Chicago, IL, USA).

Results
=======

Clinical and endoscopic features of the study patients
------------------------------------------------------

The mean age of the 24 study patients with non-curatively resected SEC was 66.3±8.3 years; 22 (91.7%) were male ([Table 1](#t1-ce-2018-025){ref-type="table"}). The tumors were located mostly in the middle third of the esophagus (58.3%), and the mean tumor size was 16.1±7.6 mm. There was one (4.2%) case of adenocarcinoma which occurred after Barrett's esophagus. On resection pathology, SM tumor invasion was evident in 21 cases and LV invasion in four cases. Both SM and LV invasions were noted in one patient. Fourteen patients received additional treatments, including surgical esophagectomy (*n*=7), concurrent chemoradiotherapy (*n*=5), and radiation therapy (*n*=2). Four (16.7%) patients received ER due to a severe comorbidity: two patients with stroke and two with severe chronic pulmonary disease. [Table 1](#t1-ce-2018-025){ref-type="table"} compares the clinical and tumor-related features of the close observation and additional therapy groups. There were no differences in age, sex, performance status, tumor location and size, and histological tumor invasions between the groups.

Immediate endoscopic outcomes
-----------------------------

[Table 2](#t2-ce-2018-025){ref-type="table"} summarizes the immediate ER outcomes of our study patients. Twenty lesions (83.3%) were resected by endoscopic SM dissection. The mean endoscopic procedure time was 51.2±32.8 minutes. ER-related complications occurred in three patients (12.5%), including one of pneumonia and two of severe stricture. The two patients with stricture were treated with endoscopic balloon dilatation. No cases of perforation or bleeding were reported.

Long-term survival and tumor recurrence
---------------------------------------

[Table 3](#t3-ce-2018-025){ref-type="table"} and [Fig. 2](#f2-ce-2018-025){ref-type="fig"} present the oncologic outcomes of the 24 study patients with non-curatively resected SEC. During a mean follow-up of 59.0±33.2 months, the 3- and 5-year survival rates of all cases were 90.7% and 77.6%, respectively. The 5-year overall survival rate was 72.9% in the close observation group and 82.1% in the additional treatment group (*p*=0.958; [Fig. 2A](#f2-ce-2018-025){ref-type="fig"}). In addition, the 5-year cumulative incidences of all cases of recurrence (25.0% vs. 43.3%, *p*=0.388; [Fig. 2B](#f2-ce-2018-025){ref-type="fig"}), primary EC recurrence (10.0% vs. 16.4%, *p*=0.558; [Fig. 2C](#f2-ce-2018-025){ref-type="fig"}), and metachronous EC (16.7% vs. 26.7%, *p*=0.667; [Fig. 2D](#f2-ce-2018-025){ref-type="fig"}) were similar between the close observation and additional treatment groups. Two patients died of a second primary cancer of the lung. [Table 4](#t4-ce-2018-025){ref-type="table"} summarizes the clinical course and treatment outcome of each study patient.

DISCUSSION
==========

We observed 3- and 5-year survival rates of 90.7% and 77.6%, respectively, in our current case series of patients with complete non-curatively resected SEC. We also found that the prognosis for our closely observed patients after non-curative ER did not significantly differ from that of the patients who underwent additional treatment. The 5-year overall survival was 72.9% in the close observation group and 82.1% in the additional treatment group, which are similar to the reported 5-year survival rates of stage I EC patients: 62%--78% after esophagectomy and 68.6%--77% with chemoradiotherapy \[[@b13-ce-2018-025]-[@b18-ce-2018-025]\]. Further, the 5-year cumulative incidences of all cases of recurrence, primary EC recurrence, and metachronous EC were comparable between groups.

Metastasis to a regional lymph node is a well-known risk factor related to the prognosis of EC \[[@b19-ce-2018-025]\]. A number of studies have estimated the risk of lymph node metastasis of SEC, particularly focused on the depth of tumor invasion and presence of LV invasion. The reported prevalence of nodal involvement is 0%--10.3% when the tumor is limited within the mucosa \[[@b2-ce-2018-025]-[@b4-ce-2018-025]\]. Considering the low risk of lymph node metastasis, these cases are indicated for ER and warrant close observation. In a retrospective cohort study of 104 SEC patients with mucosal invasion, overall and cause-specific survival rates at 5 years after ER were 79.5% and 95.0%, respectively, during the median follow-up period of 43 months \[[@b20-ce-2018-025]\]. Based on a pathologic analysis of 190 SEC patients who underwent esophagectomy, we previously reported that ER should be performed for mucosal cancers ≤3 cm \[[@b11-ce-2018-025]\]. Moreover, if the pathology of the resected specimens reveals invasion of the SM1 layer and a lower mucosal invasion width of ≤3.0 mm, the patient can be carefully observed without additional treatment.

Additional treatments for SEC patients with SM or LV invasion after ER are currently accepted as the appropriate course. Although guidelines for selecting the additional therapy are limited, esophagectomy or chemoradiotherapy are typical modalities \[[@b20-ce-2018-025]-[@b22-ce-2018-025]\]. However, there are few clinical data on the benefits of additional treatment in terms of the long-term prognosis of non-curatively resected SEC patients. A previous study compared the prognosis of 26 SEC patients with tumor invasion to the mucosa or upper third of the submucosa solely treated with ER with that of those treated with esophagectomy \[[@b23-ce-2018-025]\]. They reported no significant difference in the 5-year overall survival rates of patients who underwent esophagectomy and those who underwent ER (84.5% and 77.4%, *p*=0.44), nor in their cause-specific survival (93.5% and 95.0%, *p*=0.73). A recent retrospective analysis of 36 esophageal SEC cases treated with ER reported the clinical course of six non-curatively resected cases \[[@b10-ce-2018-025]\]. Five of these patients received additional treatment and one patient was closely observed. During the median follow-up of 31 months, the authors reported no recurrence in the closely observed patients. Among the five patients who underwent additional treatment, one who underwent esophagectomy experienced lymph node recurrence 24 months after the operation and required chemoradiotherapy. In our previous ER data with SEC cohort, a 5-year cumulative survival rate of 79.1% was noted in patients with SEC invading the submucosa \[[@b12-ce-2018-025]\].

The similar prognosis of SEC patients receiving close observation and those receiving additional treatments after non-curative ER may be explained by treatment-related complications and the occurrences of metachronous EC or second primary cancers. The perioperative mortality rates after esophagectomy reportedly range from 2.7% to 13.3% \[[@b4-ce-2018-025]-[@b7-ce-2018-025]\]. In addition, a significant proportion of patients who undergo chemoradiotherapy experience severe toxicity and even death \[[@b24-ce-2018-025]\]. Our institutional data indicate post-operative mortality and morbidity rates of 2.1% and 37.5%, respectively, in patients receiving upfront surgery and chemoradiotherapy-related death and toxicity rates of 3.9% and 24%, respectively \[[@b25-ce-2018-025]\].

Metachronous EC or second primary cancers in other organs are additional concerns following ER for SEC. Indeed, the reported 5-year cumulative incidence of metachronous EC is 16.8%--24.5% \[[@b26-ce-2018-025]-[@b28-ce-2018-025]\]. In a previous pooled analysis, the 10-year cumulative risk of second primary malignancy after esophagectomy was 34.5% with an overall relative risk of 2.98 \[[@b8-ce-2018-025]\]. The risk of head and neck cancer was markedly elevated, followed by the risks of lung cancer and stomach cancer. The 5-year survival rate after the detection of subsequent malignancy was 45%. We previously reported a 6.6% incidence of second primary cancers in EC patients at diagnosis and a poor prognosis in these patients with 3- and 5-year survival rates of 25.0% and 10.6%, respectively \[[@b9-ce-2018-025]\]. In the present case series, the 5-year cumulative incidence of metachronous EC was 16.7% in the close observation group and 26.7% in the additional treatment group. The three patients with metachronous EC were treated with subsequent surgery or ER and were all alive during the follow-up period. On the other hand, two of our patients died of second primary cancers of the lung.

The limitation of the current study includes its small number of patients and use of retrospectively collected data in a single institution. However, the results of the current study provide important clues for understanding the pattern, disease course, and prognosis of EC recurrence after non-curative resection.

In summary, our current case series of SEC patients showed good long-term survival outcomes after complete non-curative ER. Given the similar oncologic outcomes compared with additional treatments, close observation may be an option with appropriate caution for patients who are medically unfit to receive additional therapy. Long-term clinical data should be accumulated to facilitate the development of appropriate treatments of SEC after non-curative ER.
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![Follow-up profile of esophageal cancer patients treated with endoscopic resection (ER). LRM, lateral resection margin; DRM, deep resection margin; RTx, radiotherapy; CCRT, concurrent chemoradiotherapy; CTx, chemotherapy.](ce-2018-025f1){#f1-ce-2018-025}

![The 5-year overall survival (A), 5-year cumulative incidences of all cases of esophageal cancer (EC) recurrence (B), primary EC recurrence (C), and metachronous EC (D) rates in the close observation and additional treatment groups.](ce-2018-025f2){#f2-ce-2018-025}

###### 

Features of the Analyzed Patients with Non-Curatively Resected Superficial Esophageal Cancer

                             Total (*n*=24)   Close observation (*n*=10)   Additional treatment (*n*=14)   *p*-value
  -------------------------- ---------------- ---------------------------- ------------------------------- -----------
  Age, yr                    66.3±8.3         68.6±8.0                     64.7±8.4                        0.270
  Sex, male (%)              22 (91.7)        10 (100)                     12 (85.7)                       0.493
  Smoking                    20 (83.3)        9 (90)                       11 (78.6)                       0.615
  Alcohol                    16 (66.7)        6 (60)                       10 (71.4)                       0.673
  Severe comorbidities       4 (16.7)         3 (30)                       1 (7.1)                         0.272
  ECOG PS                                                                                                  1.000
   1                         20 (83.3)        8 (80)                       12 (85.7)                       
   2                         4 (16.7)         2 (20)                       2 (14.3)                        
  Tumor location                                                                                           0.941
   Upper                     2 (8.3)          1 (10)                       1 (7.1)                         
   Middle                    14 (58.3)        6 (60)                       8 (57.1)                        
   Lower                     8 (33.3)         3 (30)                       5 (35.7)                        
  Macroscopic type                                                                                         0.095
   Elevated                  13 (54.2)        3 (30)                       10 (71.4)                       
   Flat                      11 (45.8)        7 (70)                       4 (28.6)                        
  Tumor size, mm             16.1±7.6         14.7±7.4                     17.2±7.8                        0.439
  Tumor histology                                                                                          
   Squamous cell carcinoma   23 (95.8)        9 (90)                       14 (100)                        0.417
   Adenocarcinoma            1 (4.2)          1 (10)                       0                               
  Tumor invasion                                                                                           
   Submucosal                21 (87.5)        8 (80)                       13 (92.9)                       0.550
   Lymphovascular            4 (16.7)         2 (20)                       2 (14.3)                        1.000

Data represent the number of patients (%) or the mean±SD.

ECOG PS, Eastern Cooperative Oncology Group performance status; SD, standard deviation.

###### 

Immediate Endoscopic Outcomes

                            Total (*n*=24)   Watchful observation (*n*=10)   Additional treatment (*n*=14)   *p*-value
  ------------------------- ---------------- ------------------------------- ------------------------------- -----------
  Resection method                                                                                           1.000
   Mucosal resection        4 (16.7)         2 (20)                          2 (14.3)                        
   Submucosal dissection    20 (83.3)        8 (80)                          12 (85.7)                       
  Procedure time, minutes   51.2±32.8        64.1±46.0                       42.0±14.9                       0.259
  Complications             3 (12.5)         2 (20)                          1 (7.1)                         0.660
   Pneumonia                1 (4.2)          0                               1 (7.1)                         
   Stricture                2 (8.3)          2 (20)                          0                               

Data represent the number of patients (%) or the mean±SD.

SD, standard deviation.

###### 

Long-Term Oncologic Outcomes

                               Total (*n*=24)   Close observation (*n*=10)   Additional treatment (*n*=14)   *p*-value
  ---------------------------- ---------------- ---------------------------- ------------------------------- -----------
  Follow-up duration, months   59.0±33.2        53.5±30.8                    62.9±35.4                       0.505
  Primary EC recurrence                                                                                      
   Locoregional lymph node     2                0                            2 (14.3)                        0.212
   Distant metastasis          2                1 (10)                       1 (7.1)                         0.803
  Recurrence period, months    36.7±26.1        11                           45.3±24.1                       0.500
  Metachronous EC              3 (12.5)         1 (10)                       2 (14.3)                        1.000
  All-cause death              5 (20.8)         2 (20)                       3 (21.4)                        1.000
  EC-related death             3 (12.5)         1 (10)                       2 (14.3)                        1.000

Data represent the number of patients (%) or the mean±SD.

EC, esophageal cancer; SD, standard deviation.

###### 

Clinical Summaries for the Non-Curatively Resected Superficial Esophageal Cancer Patients

  Case no.   Age, yr/sex   Comorbidity   Tumor location   Tumor size (mm)   Tumor invasion   Additional treatment   Primary EC recurrence, mo   Metachronous EC, mo   Treatment for recurred tumor   Survival, mo   Cause of death
  ---------- ------------- ------------- ---------------- ----------------- ---------------- ---------------------- --------------------------- --------------------- ------------------------------ -------------- ----------------
  1          59/M          \-            Middle           6×5               SM               \-                     \-                          Yes, 47               Surgery                        92             Alive
  2          75/M          \-            Middle           9×8               SM               \-                     \-                          \-                    \-                             83             Alive
  3          68/M          Stroke-       Middle           20×13             SM               \-                     \-                          \-                    \-                             83             Alive
  4          74/M          \-            Middle           30×16             LV               \-                     \-                          \-                    \-                             32             Alive
  5          86/M          Stroke        Middle           9×6               SM               \-                     \-                          \-                    \-                             75             Alive
  6          62/M          \-            Lower            20×12             LV               \-                     \-                          \-                    \-                             15             Alive
  7          61/M          \-            Lower            11×9              SM               \-                     \-                          \-                    \-                             61             Alive
  8          68/M          COPD          Middle           28×22             SM               \-                     Lung, 11                    \-                    CTx                            17             EC
  9          67/M          \-            Upper            10×10             SM               \-                     \-                          \-                    \-                             60             LC
  10         66/M          \-            Lower            25×25             SM               \-                     \-                          \-                    \-                             16             Alive
  11         69/M          COPD          Lower            25×15             SM               CCRT                   \-                          \-                    \-                             45             Alive
  12         72/M          \-            Middle           8×5               SM               Surgery                \-                          \-                    \-                             126            Alive
  13         63/M          \-            Lower            30×15             SM               RTx                    \-                          Yes, 56               ER                             105            Alive
  14         59/M          \-            Middle           25×12             LV               RTx                    \-                          Yes, 31               Surgery                        129            Alive
  15         62/M          \-            Upper            11×6              SM               Surgery                \-                          \-                    \-                             86             Alive
  16         73/M          \-            Lower            21×18             SM               Surgery                \-                          \-                    \-                             42             LC
  17         71/M          \-            Middle           7×6               SM, LV           Surgery                Lung/spine, 72              \-                    Supportive                     75             EC
  18         60/M          \-            Middle           36×22             SM               CCRT                   LN, 39                      \-                    RTx                            60             Alive
  19         58/M          \-            Middle           15×10             SM               Surgery                \-                          \-                    \-                             47             Alive
  20         69/M          \-            Middle           34×22             SM               CCRT                   \-                          \-                    \-                             33             Alive
  21         71/M          \-            Lower            25×12             SM               Surgery                \-                          \-                    \-                             41             Alive
  22         44/F          \-            Middle           10×10             SM               CCRT                   \-                          \-                    \-                             35             Alive
  23         76/M          \-            Lower            35×17             SM               CCRT                   LN, 26                      \-                    Supportive                     30             EC
  24         59/F          \-            Middle           15×12             SM               Surgery                \-                          \-                    \-                             27             Alive

EC, esophageal cancer; SM, submucosal; LV, lymphovascular; COPD, chronic obstructive pulmonary disease; CTx, chemotherapy; LC, lung cancer; CCRT, concurrent chemoradiotherapy; RTx, radiotherapy; ER, endoscopic resection; LN, regional lymph node.
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